CME/CE Credits

CME/CE Credits Available CME/CE Credits Available Pharmacology Credit Available*
Opening Panel: AP Leadership in Times of Crisis 0.75 0
Advanced Prostate Cancer: Considerations for Advanced Practitioners 0.75 0.50
Case Studies in AL and ATTR Amyloidosis 0.75 0.25
New Drug Updates: Solid Tumors 0.75 0.75
The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations 0.75 0.50
FDA and its Role in Drug Development 0.50 0.50
Kidney Cancer: Tracking and Treating Symptoms With the Challenge of Combination Therapy 0.50 0.25
Sticky Issues: What APs Need to Know About Anticoagulants And Patients With Cancer 0.50 0.50
The Mary Pazdur Award Presentation Followed by the Keynote Interview: Words Matter: Use of Respectful Language in Oncology 0.75 0
Developments in Hepatocellular Cancer Treatment 0.75 0.25
Sarcoma: Disease Overview and a Case-Based Approach to Treatment Updates 0.50 0.25
Hemolytic Anemias: Autoimmune and Beyond 0.50 0.25
Approaches to Treating the Hospitalized Patient With Thrombocytopenia 0.50 0.25
Infrequent Offenders: Neuroendocrine Tumors and Cancers of the Appendix, Gallbladder, and Bile Duct 0.75 0
Biomarker Jeopardy 0.75 0.75
Management of Diabetes in the Patient With Cancer 0.50 0.25
Cardio-Oncology: The Intersection of Cardiovascular Disease and Cancer 0.75 0.25
Immune Checkpoint Inhibitors: Common Questions About Uncommon Adverse Events 0.75 0.75
Mitigating the Morbidity of Financial Toxicity in Cancer Care 0.50 0
Optimizing Treatment of Chronic Lymphocytic Leukemia 0.75 0.50
A Multidisciplinary Approach to Head and Neck Cancer 0.50 0.25
The Elevator Pitch: Communicating Your Expertise, Experience, and Value to Patients, Co-Workers, and Prospective Employers in an Instant 0.75 0
New Drug Updates: Hematologic Malignancies 0.75 0.75
Improving Outcomes in Hematopoietic Stem Cell Transplant: Recent Advances 0.50 0.25
Are Current Metrics Adequate to Demonstrate the Value of the Oncology AP? 0.50 0
Total Credits Available 16.0 8.0

Additional credits available:

Independent CE Satellite Symposium brought to you be Integrity Continuing Education: From Sledgehammer to Selective: Transforming Cytotoxic Potency Through Targeted Treatments for Advanced or Metastatic Urothelial Cancer

Register at:

Claim your credits through the Integrity CE website

1.25 TBD

NOTE: Presentations are offered more than once. You may only claim credit once per presentation by attending either a Premiere or Encore (Live) session, or an On-demand (Enduring) session. A maximum of 16 credits may be earned and claimed from the CE Portal.

*Pharmacology credits will be on the ANCC certificate only.